dc.contributor.author | Glynn, D | |
dc.contributor.author | Bliss, J | |
dc.contributor.author | Brunt, AM | |
dc.contributor.author | Coles, CE | |
dc.contributor.author | Wheatley, D | |
dc.contributor.author | Haviland, JS | |
dc.contributor.author | Kirby, AM | |
dc.contributor.author | Longo, F | |
dc.contributor.author | Faria, R | |
dc.contributor.author | Yarnold, JR | |
dc.contributor.author | Griffin, S | |
dc.date.accessioned | 2022-11-23T09:12:41Z | |
dc.date.available | 2022-11-23T09:12:41Z | |
dc.date.issued | 2022-11-17 | |
dc.identifier.citation | Breast Cancer Research and Treatment, 2022, | |
dc.identifier.issn | 0167-6806 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5568 | |
dc.identifier.eissn | 1573-7217 | |
dc.identifier.eissn | 1573-7217 | |
dc.identifier.doi | 10.1007/s10549-022-06802-1 | |
dc.description.abstract | PURPOSE: We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) radiotherapy delivered in either 15 (WB15F, PB15F) or 5 fractions (WB5F, PB5F). In a subgroup ineligible for PB radiotherapy, we compared WB15F to WB5F. METHODS: We developed a Markov cohort model to simulate lifetime healthcare costs and quality-adjusted life years (QALYs) for each modality. This was informed by the clinical analysis of two non-inferiority trials (FAST Forward and IMPORT LOW) and supplemented with external literature. The primary analysis assumed that radiotherapy modality influences health only through its impact on locoregional recurrence and radiotherapy-related adverse events. RESULTS: In the primary analysis, PB5F had the least cost and greatest expected QALYs. WB5F had the least cost and the greatest expected QALYs in those only eligible for WB radiotherapy. Applying a cost-effectiveness threshold of £15,000/QALY, there was a 62% chance that PB5F was the cost-effective alternative in the PB eligible group, and there was a 100% chance that WB5F was cost-effective in the subgroup ineligible for PB radiotherapy. CONCLUSIONS: Hypofractionation to 5 fractions and partial breast radiotherapy modalities offer potentially important benefits to the UK health system. | |
dc.language | en | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.relation.ispartof | Breast Cancer Research and Treatment | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-10-18 | |
dc.date.updated | 2022-11-22T15:38:03Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1007/s10549-022-06802-1 | |
rioxxterms.licenseref.startdate | 2022-11-17 | |
rioxxterms.type | Journal Article/Review | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1007/s10549-022-06802-1 | |
icr.researchteam | Clin Trials & Stats Unit | |
dc.contributor.icrauthor | Bliss, Judith | |
dc.contributor.icrauthor | Yarnold, John | |
icr.provenance | Deposited by Mrs Jessica Perry (impersonating Prof Judith Bliss) on 2022-11-22. Deposit type is initial. No. of files: 1. Files: HE paper published version - breast cancer research and treatment Nov 2022.pdf | |